Vertex a Buy, Nvidia Taking Supercomputing to New Heights, TriQuint in New iPhone
Vertex Pharmaceuticals has sold off the past few weeks based on fears of lower than hoped-for sales of its leading hepatitis C compound, as well as new competition nibbling at its heels. I think the company is now oversold for several reasons.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Technology Profits Confidential
With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.